Table 2. Summary of Ewing’s sarcoma ‘n of 1’ study results.

Model	DC101	Doxorubicin	Combination
	% ΔT/C or regression*
CTG-0143	153	176	66.4
CTG-1651	8.4	57.4	−12.1
CTG-1663	29.2	44	20.7
CTG-2003	101	42.8	103
CTG-2113	54.6	12.3	39.6
CTG-2174	54.5	3.1	52.1

^*at end of treatment (Day 28) or date of sacrifice if prior to end of treatment.